Clinical Trials Logo

Filter by:
NCT ID: NCT06030115 Completed - Cardiac Surgery Clinical Trials

Effects of a Hybrid Model of Cardiac Rehabilitation on Patient Outcomes

Start date: July 1, 2019
Phase:
Study type: Observational

Determine if the standard of care at a cardiac rehabilitation center using what the investigators term to be "hybrid model" on the exercise component of cardiac rehabilitation is associated with improved adherence and outcomes. Discuss the hybrid model in comparison to traditional cardiac rehabilitation and layout a template on how to incorporate this hybrid model. Discuss factors that may lead to poor adherence and attendance to cardiac rehabilitation.

NCT ID: NCT06029452 Completed - ATTR-CM Clinical Trials

A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).

Start date: September 1, 2023
Phase:
Study type: Observational

This is an observational, retrospective non-inferiority study with a study sample from a large national database. A machine learning (ML) model will use a national database to predict the clinical diagnosis of ATTRwt-CM among HF patients. This study will include HF patients ≥50 years old.

NCT ID: NCT06029010 Completed - Clinical trials for Metastatic Colorectal Cancer

An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States

COLONGER
Start date: August 31, 2023
Phase:
Study type: Observational

This is an observational study in which data already collected from patients with metastatic colorectal cancer will be studied. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part of the bowel just before the anus) that has spread to other parts of the body. The study drug, regorafenib, is already approved for cancer doctors to prescribe to patients with mCRC. It is an anti-cancer drug that blocks several proteins, called enzymes, which are involved in the growth of cancer. The participants in this study were treated with regorafenib as part of their regular care from their doctors. Some studies have shown that patients with mCRC who took regorafenib had improved survival outcomes, and some of them did well on the treatment for a long time. Cancer doctors have also reported from their routine practice that some patients with mCRC are able to respond to regorafenib for a longer period than others. However, there is limited knowledge about which people this is likely to happen for. To better understand the long-term response of regorafenib treatment, there is a need for a large-scale study in the real world. The main purpose of this study is to learn more about patients who showed a long-term response to regorafenib as a mono treatment for mCRC. To do this, researchers will collect the following information from the participants' health records: Duration of treatment with regorafenib Percentage of participants who received treatment with regorafenib for at least 5 months and 4 months. Characteristics, including age, sex, race, health condition, and signs and symptoms of mCRC, of participants who received treatment with regorafenib for at least 5 months and 4 months. The data will come from an electronic health records database called the Flatiron Health Data Repository for patients in the United States. The data will be from patients with mCRC who started treatment with regorafenib between July 2013 and December 2022. Researchers will consider the data of the participants collected until May 2023. In this study, only available data from routine care are collected. No visits or tests are required as part of this study.

NCT ID: NCT06028152 Completed - Breast Cancer Clinical Trials

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning

Start date: October 31, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with breast, lung, and/or genito-urinary cancers treated at Penn State Cancer Institute and their loved ones perform advance care planning. The main questions it aims to answer are: - What modifications and/or adaptations are necessary to Hello for use in cancer populations? - How do different delivery models compare for recruitment in terms of feasibility and efficiency? Participants will: - Complete pre-game questionnaires - Play the Hello game - Complete post-game questionnaires - Participate in a focus group

NCT ID: NCT06028035 Completed - Clinical trials for Irritable Bowel Syndrome-bile Acid Diarrhea

A Study of Hemp Hull WFI for IBS Diarrhea

Start date: October 6, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is the effect of a study bar, which contains 15 grams of insoluble dietary fiber total sourced from Hemp hulls, on intestinal permeability in irritable bowel syndrome (IBS)-bile acid diarrhea individuals.

NCT ID: NCT06027437 Completed - Healthy Volunteers Clinical Trials

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

Start date: September 5, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the relative biological availability and the effect of food on the drug levels of Danicamtiv in health adults.

NCT ID: NCT06027164 Completed - Cardiac Disease Clinical Trials

Kosmos Trio and Ejection Fraction Pivotal Study

Start date: August 4, 2023
Phase:
Study type: Observational

This is a single-group, observational study which will involve obtaining two echo scans of recruited patients. All recruited patients will undergo echo scans by both novice users (nurses) and experts (echo sonographers). Image quality between novices and experts as well as the ability to calculate LVEF from novice and expert scans and the quality of the LVEF calculated via KOSMOS-EF compared to LVEF calculations by expert cardiologists will occur in post-hoc Echo image analysis

NCT ID: NCT06026397 Completed - Clinical trials for Chemotherapy-induced Diarrhea

A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects

Start date: August 1, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of orally administered SK10 powders in healthy adult subjects at three dose levels, following single and multiple doses.

NCT ID: NCT06025708 Completed - Clinical trials for Coagulation Defect; Bleeding

Quantra QStat Sample Type Comparison

Start date: September 11, 2023
Phase:
Study type: Observational

This is a single center prospective observational study to compare QStat parameter measurements in arterial and venous blood samples collected in parallel from patients undergoing liver transplantation.

NCT ID: NCT06025396 Completed - Healthy Volunteers Clinical Trials

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

Start date: January 6, 2023
Phase: Phase 1
Study type: Interventional

A PHASE 1, RANDOMIZED, PLACEBO CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TMP-301 IN HEALTHY SUBJECTS.